K

KMPharmaceutical Co Ltd
KOSDAQ:225430

Watchlist Manager
KMPharmaceutical Co Ltd
KOSDAQ:225430
Watchlist
Price: 532 KRW -1.12% Market Closed
Market Cap: 14.8B KRW

Intrinsic Value

The intrinsic value of one KMPharmaceutical Co Ltd stock under the Base Case scenario is 492.72 KRW. Compared to the current market price of 532 KRW, KMPharmaceutical Co Ltd is Overvalued by 7%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
492.72 KRW
Overvaluation 7%
Intrinsic Value
Price
K
Worst Case
Base Case
Best Case

Valuation History
KMPharmaceutical Co Ltd

What is Valuation History?
Ask AI Assistant
What other research platforms think about KMPharmaceutical Co Ltd?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is KMPharmaceutical Co Ltd valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for KMPharmaceutical Co Ltd.

Explain Valuation
Compare KMPharmaceutical Co Ltd to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about KMPharmaceutical Co Ltd?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
KMPharmaceutical Co Ltd

Current Assets 4.7B
Cash & Short-Term Investments 810m
Receivables 1.3B
Other Current Assets 2.6B
Non-Current Assets 44.3B
Long-Term Investments 14.7B
PP&E 21.1B
Intangibles 14.2m
Other Non-Current Assets 8.4B
Current Liabilities 9.3B
Accounts Payable 998.7m
Accrued Liabilities 856.9m
Short-Term Debt 4B
Other Current Liabilities 3.5B
Non-Current Liabilities 7B
Long-Term Debt 7B
Other Non-Current Liabilities 41.9m
Efficiency

Free Cash Flow Analysis
KMPharmaceutical Co Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
KMPharmaceutical Co Ltd

Revenue
14B KRW
Cost of Revenue
-10.7B KRW
Gross Profit
3.3B KRW
Operating Expenses
-5.8B KRW
Operating Income
-2.5B KRW
Other Expenses
-2.1B KRW
Net Income
-4.6B KRW
Fundamental Scores

Profitability Score
Profitability Due Diligence

KMPharmaceutical Co Ltd's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

Healthy Gross Margin
Sustainable 3Y Average Gross Margin
Gross Margin is Increasing
Declining Net Margin
29/100
Profitability
Score

KMPharmaceutical Co Ltd's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

KMPharmaceutical Co Ltd's solvency score is 29/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Low D/E
Short-Term Solvency
Positive Net Debt
29/100
Solvency
Score

KMPharmaceutical Co Ltd's solvency score is 29/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
KMPharmaceutical Co Ltd

There are no price targets for KMPharmaceutical Co Ltd.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

KMPharmaceutical Co Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for KMPharmaceutical Co Ltd is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one KMPharmaceutical Co Ltd stock?

The intrinsic value of one KMPharmaceutical Co Ltd stock under the Base Case scenario is 492.72 KRW.

Is KMPharmaceutical Co Ltd stock undervalued or overvalued?

Compared to the current market price of 532 KRW, KMPharmaceutical Co Ltd is Overvalued by 7%.

Back to Top